fatty diacid raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Finasteride, sold under the brand names Proscar (5 mg) and Propecia (1 mg) among others, is a medication used to treat pattern hair loss and benign prostatic hyperplasia (BPH). It can also be used to treat excessive hair growth in women. It is usually taken orally but there are topical formulations for patients with hair loss, designed to minimize systemic exposure by acting specifically on hair follicles. Along with dutasteride, finasteride is a widely dispensed 5α-reductase inhibitor. As such, it is an antiandrogen that works by decreasing the production of dihydrotestosterone (DHT) by about 70% in serum, 65-70% in scalp skin, 90% in prostate. In addition to DHT, finasteride also inhibits the production of several anticonvulsant neurosteroids including allopregnanolone, androstanediol, and tetrahydrodeoxycorticosterone. Adverse effects from finasteride are rare in men with already enlarged prostates; however, some men experience sexual dysfunction, depression, and breast enlargement. In some men, sexual dysfunction may persist after stopping the medication. It may also hide the early symptoms of certain forms of prostate cancer. Finasteride was patented in 1984 and approved for medical use in 1992. It is available as a generic medication. In 2023, it was the 91st most commonly prescribed medication in the United States, with more than 7 million prescriptions.
=== Bioavailability === In contrast to the intake of CoQ10 as a constituent of food, such as nuts or meat, from which CoQ10 is normally absorbed, there is a concern about CoQ10 bioavailability when it is taken as a dietary supplement. Bioavailability of CoQ10 supplements may be reduced due to the lipophilic nature of its molecule and large molecular weight.
The ELP tags have been used in the fusion protein of intein, so that the aggregates can be isolated without chromatography (by centrifugation) and then intein and tag can be cleaved in controlled manner to release the target protein into solution. This protein isolation can be done using continuous media flow, yielding high amounts of protein, making this process more economically efficient than conventional methods. Another group of researchers used smaller self aggregating tags to isolate target protein. Small amphipathic peptides 18A and ELK16 (figure 5) were used to form self cleaving aggregating protein.
Sources: en.wikipedia.org
In the colon, for example, the muscular layer is much thicker because the faeces are large and heavy and require more force to push along. The outer longitudinal layer of the colon thins out into 3 discontinuous longitudinal bands, known as taeniae coli (bands of the colon). This is one of the 3 features helping to distinguish between the large and small intestine. Occasionally in the large intestine (2-3 times a day), there will be mass contraction of certain segments, moving a lot of faeces along. This is generally when one gets the urge to defecate. The pylorus of the stomach has a thickened portion of the inner circular layer: the pyloric sphincter. Alone among the GI tract, the stomach has a third layer of muscular layer. This is the inner oblique layer and helps churn the chyme in the stomach.
== History == The ability of a soapy solution to act as a detergent has been recognized for centuries. However, it was only at the beginning of the twentieth century that the constitution of such solutions was scientifically studied. Pioneering work in this area was carried out by James William McBain at the University of Bristol. As early as 1913, he postulated the existence of "colloidal ions" to explain the good electrolytic conductivity of sodium palmitate solutions. These highly mobile, spontaneously formed clusters came to be called micelles, a term borrowed from biology and popularized by G.S. Hartley in his classic book Paraffin Chain Salts: A Study in Micelle Formation. The term micelle was coined in nineteenth century scientific literature as the ‑elle diminutive of the Latin word mica (particle), conveying a new word for "tiny particle".
== Structure == Aggrecanase is a very large molecule. Its size is estimated to be around 2.5 million Daltons. The molecule is built from a core protein that weighs about 250 kilodaltons. The molecule is made of multiple subunits, each with a specific function. It has a signal sequence of about 170 amino acids in length. The purpose of this sequence is to direct the protein to the correct location of the cell. Another subunit is the pre domain, the metalloproteinase domain, which is around 230 amino acids in length. Its purpose is to keep the enzyme inactive until necessary. Another way the enzyme will remain inactive is in the absence of its catalytic region, which is dependent on zinc ion. Its purpose is to help bind the molecule and stabilize interactions. Attached to the core protein are glycosaminoglycans, a long chain of negatively charged polysaccharides. These glycosaminoglycans consist of chondroitin sulfate and keratan sulfate. The glycosaminoglycans being negatively charged, allow the aggrecan to hold large amounts of water. This is beneficial to the molecule because aggrecanase is a part of connective tissue, cartilage. The water allows the cartilage to better resist pressure when the joints it protects are compressed. This is because the water does not allow it to collapse, but instead spring back and maintain its structure.
== See also == List of UFC champions List of UFC events List of current UFC fighters 2026 in Professional Fighters League 2026 in ONE Championship 2026 in Konfrontacja Sztuk Walki 2026 in Legacy Fighting Alliance 2026 in Absolute Championship Akhmat 2026 in Rizin Fighting Federation 2026 in LUX Fight League 2026 in Oktagon MMA 2026 in Cage Warriors
Sources: en.wikipedia.org
Pa s. This is about a ten thousand times that of water at room temperature, but it is small enough to enable the LAF-1 droplets to flow like a liquid. Generally, interaction strength (affinity) and valence (number of binding sites) of the phase separating biomolecules influence their condensates viscosity, as well as their overall tendency to phase separate.
=== Research tool === Due to its high proteolytic specificity, thrombin is a valuable biochemical tool. The thrombin cleavage site (Leu-Val-Pro-Arg-Gly-Ser) is commonly included in linker regions of recombinant fusion protein constructs. Following purification of the fusion protein, thrombin can be used to selectively cleave between the arginine and glycine residues of the cleavage site, effectively removing the purification tag from the protein of interest with a high degree of specificity.
Droplet countercurrent chromatography (DCCC or DCC) was introduced in 1970 by Tanimura, Pisano, Ito, and Bowman. DCCC is considered to be a form of liquid-liquid separation, which includes countercurrent distribution and countercurrent chromatography, that employs a liquid stationary phase held in a collection of vertical glass columns connected in series. The mobile phase passes through the columns in the form of droplets. The DCCC apparatus may be run with the lower phase stationary and the upper phase being introduced to the bottom of each column. Or it may be run with the upper phase stationary and the lower phase being introduced from the top of the column. In both cases, the work of gravity is allowed influence the two immiscible liquids of different densities to form the signature droplets that rise or descend through the column. The mobile phase is pumped at a rate that will allow droplets to form that maximize the mass transfer of a compound between the upper and lower phases. Compounds that are more soluble in the upper phase will travel quickly through the column, while compounds that are more soluble in the stationary phase will linger. Separation occurs because different compounds distribute differently, in a ratio called the partition coefficient, between the two phases. The biphasic solvent system must be carefully formulated so that it will perform appropriately in the DCCC column. The solvent system must form two phases without excess emulsification in order to form droplets.
Traditionally, Parkinson's disease has been considered a non-genetic disorder. However, between 15 and 25% of people with PD report familial connections who have PD, and from 10 to 20% have a first-degree relative with PD. No single-gene mutation in PD causes PD, but multiple genetic factors can increase susceptibility and the risk of developing either familial or sporadic PD. More penetrant PD mutations with a higher risk of developing the disease, tend to be rare but are often associated with familial PD (e.g. rare SNCA variants). A second group of variants (including GBA and LRRK2 variants) are uncommon and carry an intermediate level of risk in a significant minority of PD cases. A third group of genetic variants occur often but carry low risk. Unequivocal links to PD pathogenesis have been found for mutations in at least six genes: LRRK2, SNCA, and VPS35 (dominant forms) and PRKN/Parkin, PINK1, and PARK7/DJ1 (recessive forms). The most extensively studied PD-related genes are LRRK2 and SNCA. At least 16 genes display "causal" variants associated with genetic predisposition for PD, through higher familial inheritance of PD or development of early-onset PD symptoms. An additional 44 novel risk loci have been associated with sporadic PD. Both autosomal dominant and autosomal recessive gene mutations have been implicated in the development of PD. Autosomal dominant genes include SNCA (PARK1, PARK4, NCAP) and VPS35 (PARK17, MEM3), which are rare but highly penetrant, and CHCHD2. LRRK2 (PARK8, DARDARIN) and GBA (GBA1) are pathogenic but have variable penetrance.
In the United States, ACT UP formed in the 1980s, and eventually formed its Treatment Action Group in part to pressure the US government to put more resources into discovering treatments for AIDS and then to speed release of drugs that were under development. The Abigail Alliance was established in November 2001 by Frank Burroughs in memory of his daughter, Abigail. The Alliance seeks broader availability of investigational drugs on behalf of terminally ill patients. In 2013, BioMarin Pharmaceutical was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.